 |
17 Diseases |  |
0 Trials |
|
0 Trials |  |
28 News |  |
- TMC647055 / J&J
[VIRTUAL] Computational methods applied to the discovery of SARS-CoV-2 inhibitors targeting the Spike glycoprotein (Room: Virtual Room) - Aug 13, 2021 - Abstract #ACSFall2021ACS_Fall_3338;
Complete models of the Spike inserted in viral membranes were simulated using the GaMD enhanced sampling method, in the absence or presence of several copies of the top four compounds obtained from VS (phthalocyanine, hypericin, TMC-647055 and quarfloxin), to evaluate the presence of other interaction sites on the Spike surface and the ability of these molecules to insert in membranes...In parallel, molecular docking and MD simulations were also performed to evaluate the capability of bovine Lactoferrin, a glycoprotein with known antiviral properties, as a potential competitive inhibitor of Spike binding to the host cell receptor ACE2. The promising computational results obtained are also supported by in vitro evidences and by a clinical trial showing that this protein exerts a significant protective role in COVID-19 patients.
- |||| samatasvir (IDX719) / Merck (MSD)
Trial completion: Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005) (clinicaltrials.gov) - Apr 23, 2015
P2, N=143, Completed, Sponsor: Merck Sharp & Dohme Corp.
The promising computational results obtained are also supported by in vitro evidences and by a clinical trial showing that this protein exerts a significant protective role in COVID-19 patients. Active, not recruiting --> Completed
- || samatasvir (IDX719) / Merck (MSD)
Trial primary completion date: Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005) (clinicaltrials.gov) - Mar 3, 2015
P2, N=143, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Trial primary completion date: Jun 2014 --> Apr 2015
- |||| TMC647055 / J&J, Olysio (simeprevir) / J&J, Medivir
Trial completion, Trial primary completion date, Combination therapy: A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Patients Infected With Chronic Genotype 1 Hepatitis C Virus (clinicaltrials.gov) - Jan 26, 2015
P2a, N=90, Completed, Sponsor: Janssen R&D Ireland
Trial primary completion date: Jun 2014 --> Apr 2015 Active, not recruiting --> Completed | Trial primary completion date: Dec 2014 --> Sep 2014
- | samatasvir (IDX719) / Merck (MSD)
Trial completion: Drug-Drug Interaction Between IDX719, Simeprevir, TMC647055 and Ritonavir When Administered in Combination in Healthy Participants (MK-1894-007) (clinicaltrials.gov) - Aug 29, 2014
P1, N=34, Completed, Sponsor: Idenix Pharmaceuticals
Active, not recruiting --> Completed | Trial primary completion date: Dec 2014 --> Sep 2014 Active, not recruiting --> Completed
- ||| TMC647055 / J&J, Olysio (simeprevir) / J&J, Medivir
Enrollment closed, Combination therapy: A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Patients Infected With Chronic Genotype 1 Hepatitis C Virus (clinicaltrials.gov) - Jul 27, 2014
P2a, N=90, Active, not recruiting, Sponsor: Janssen R&D Ireland
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || TMC647055 / J&J, Olysio (simeprevir) / J&J, Medivir
Trial primary completion date, Combination therapy: A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Patients Infected With Chronic Genotype 1 Hepatitis C Virus (clinicaltrials.gov) - Jun 27, 2014
P2a, N=86, Recruiting, Sponsor: Janssen R&D Ireland
Recruiting --> Active, not recruiting Trial primary completion date: Aug 2015 --> Jan 2015
- TMC647055 / J&J, Olysio (simeprevir) / J&J, Medivir
Trial primary completion date, Combination therapy: A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of TMC647055 in Combination With Ritonavir (Part 1) and the Co-administration of TMC435, TMC647055 and Ritonavir (Part 2) in Healthy Japanese Participants (clinicaltrials.gov) - May 14, 2014
P1, N=24, Completed, Sponsor: Janssen R&D Ireland
Trial primary completion date: Aug 2015 --> Jan 2015 Trial primary completion date: Jun 2014 --> Apr 2014
- TMC647055 / J&J, Olysio (simeprevir) / J&J, Medivir
Trial completion date, Combination therapy: A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of TMC647055 in Combination With Ritonavir (Part 1) and the Co-administration of TMC435, TMC647055 and Ritonavir (Part 2) in Healthy Japanese Participants (clinicaltrials.gov) - May 14, 2014
P1, N=24, Completed, Sponsor: Janssen R&D Ireland
Trial primary completion date: Jun 2014 --> Apr 2014 Trial completion date: Jun 2014 --> Apr 2014
- | TMC647055 / J&J, Olysio (simeprevir) / J&J, Medivir
Trial completion, Combination therapy: A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of TMC647055 in Combination With Ritonavir (Part 1) and the Co-administration of TMC435, TMC647055 and Ritonavir (Part 2) in Healthy Japanese Participants (clinicaltrials.gov) - May 14, 2014
P1, N=24, Completed, Sponsor: Janssen R&D Ireland
Trial completion date: Jun 2014 --> Apr 2014 Recruiting --> Completed
- TMC647055 / J&J, Olysio (simeprevir) / J&J, Medivir
Enrollment change, Combination therapy: A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of TMC647055 in Combination With Ritonavir (Part 1) and the Co-administration of TMC435, TMC647055 and Ritonavir (Part 2) in Healthy Japanese Participants (clinicaltrials.gov) - May 8, 2014
P1, N=24, Recruiting, Sponsor: Janssen R&D Ireland
Recruiting --> Completed N=48 --> 24
- TMC647055 / J&J, Olysio (simeprevir) / J&J, Medivir
Enrollment open, Combination therapy: A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of TMC647055 in Combination With Ritonavir (Part 1) and the Co-administration of TMC435, TMC647055 and Ritonavir (Part 2) in Healthy Japanese Participants (clinicaltrials.gov) - Mar 27, 2014
P1, N=48, Recruiting, Sponsor: Janssen R&D Ireland
N=48 --> 24 Not yet recruiting --> Recruiting
- | TMC647055 / J&J, Olysio (simeprevir) / J&J, Medivir
New P1 trial, Combination therapy: A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of TMC647055 in Combination With Ritonavir (Part 1) and the Co-administration of TMC435, TMC647055 and Ritonavir (Part 2) in Healthy Japanese Participants (clinicaltrials.gov) - Feb 13, 2014
P1, N=48, Recruiting, Sponsor: Janssen R&D Ireland
- TMC647055 / J&J, Incivek (telaprevir) / J&J, Vertex, Mitsubishi Tanabe
Trial completion, Combination therapy: Study to Examine Multiple Doses of TMC647055 in Combination With Telaprevir (clinicaltrials.gov) - Feb 13, 2014
P1, N=7, Completed, Sponsor: Janssen R&D Ireland
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||| samatasvir (IDX719) / Merck (MSD)
Enrollment closed: Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005) (clinicaltrials.gov) - Jan 15, 2014
P2, N=143, Active, not recruiting, Sponsor: Idenix Pharmaceuticals
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| samatasvir (IDX719) / Merck (MSD)
Enrollment change: Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005) (clinicaltrials.gov) - Dec 3, 2013
P2, N=143, Active, not recruiting, Sponsor: Idenix Pharmaceuticals
Recruiting --> Active, not recruiting N=90 --> 143
- ||| TMC647055 / J&J, Olysio (simeprevir) / J&J, Medivir
Enrollment change, Combination therapy: A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Patients Infected With Chronic Genotype 1 Hepatitis C Virus (clinicaltrials.gov) - Dec 1, 2013
P2a, N=86, Recruiting, Sponsor: Janssen R&D Ireland
N=90 --> 143 N=46 --> 86
- samatasvir (IDX719) / Merck (MSD)
Enrollment closed: Drug-Drug Interaction Between IDX719, Simeprevir, TMC647055 and Ritonavir When Administered in Combination in Healthy Participants (MK-1894-007) (clinicaltrials.gov) - Aug 7, 2013
P1, N=32, Active, not recruiting, Sponsor: Idenix Pharmaceuticals
N=46 --> 86 Recruiting --> Active, not recruiting
- | samatasvir (IDX719) / Merck (MSD)
New P1 trial: Drug-Drug Interaction Between IDX719, Simeprevir, TMC647055 and Ritonavir When Administered in Combination in Healthy Participants (MK-1894-007) (clinicaltrials.gov) - Jul 23, 2013
P1, N=32, Active, not recruiting, Sponsor: Idenix Pharmaceuticals
- ||||| samatasvir (IDX719) / Merck (MSD)
New P2 trial: Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005) (clinicaltrials.gov) - May 12, 2013
P2, N=143, Active, not recruiting, Sponsor: Idenix Pharmaceuticals
- TMC647055 / J&J, Incivek (telaprevir) / J&J, Vertex, Mitsubishi Tanabe
Enrollment change, Combination therapy: Study to Examine Multiple Doses of TMC647055 in Combination With Telaprevir (clinicaltrials.gov) - Apr 17, 2013
P1, N=7, Completed, Sponsor: Janssen R&D Ireland
Recruiting --> Active, not recruiting N=16 --> 7
- ||||| TMC647055 / J&J, Olysio (simeprevir) / J&J, Medivir
New P2a trial, Combination therapy: A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Patients Infected With Chronic Genotype 1 Hepatitis C Virus (clinicaltrials.gov) - Nov 7, 2012
P2a, N=86, Recruiting, Sponsor: Janssen R&D Ireland
- TMC647055 / J&J, Incivek (telaprevir) / J&J, Vertex, Mitsubishi Tanabe
New P1 trial, Combination therapy: Study to Examine Multiple Doses of TMC647055 in Combination With Telaprevir (clinicaltrials.gov) - Apr 18, 2012
P1, N=7, Completed, Sponsor: Janssen R&D Ireland
- ||| TMC647055 / J&J, Olysio (simeprevir) / J&J, Medivir
Trial completion, Combination therapy: TMC647055HPC1001 - First-in-human Trial to Examine Safety, Tolerability and Pharmacokinetics (How the Drug is Absorbed Into the Bloodstream) of Increasing Single Oral Doses and of Increasing Repeated Oral Doses of TMC647055 in Healthy Volunteers and in Hepatitis C Virus Infected Patients (clinicaltrials.gov) - Dec 14, 2011
P1, N=72, Completed, Sponsor: Tibotec Pharmaceuticals, Ireland
N=16 --> 7 Active, not recruiting --> Completed